Obstacles to improving outcomes in the treatment of uveal melanoma

被引：20

作者：

Tsai, Katy K. ^{[1
]}

Bollin, Kathryn B. ^{[2
]}

Patel, Sapna P. ^{[3
]}

机构：

[1] Univ Calif San Francisco, Cutaneous Oncol, Hellen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

[2] Scripps Clin, Div Hematol & Oncol, La Jolla, CA 92037 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA

来源：

CANCER | 2018年 / 124卷 / 13期

基金：

美国国家卫生研究院;

关键词：

barriers; challenges; outcomes; success; therapy; treatment; trials; uveal melanoma; INTRAARTERIAL HEPATIC FOTEMUSTINE; DEPENDENT PROBE AMPLIFICATION; GENE-EXPRESSION PROFILE; LIVER METASTASES; CHOROIDAL MELANOMA; DOUBLE-BLIND; PROGNOSTIC IMPLICATIONS; UNTREATED MELANOMA; COMPLETE RESECTION; TUMOR DIAMETER;

D O I：

10.1002/cncr.31284

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The rate of advances in uveal melanoma has not kept pace with the rate of advances in cutaneous melanoma. Many patients lack access to or knowledge of specialty centers, and integrated multidisciplinary care between ophthalmology, radiation oncology, and medical oncology is far from the norm. This treatment isolation leads to limited communication about novel clinical trial opportunities. Clinical trials themselves are not widely available, and a lack of robust funding limits rapid and complete investigations. This review outlines the obstacles to success in uveal melanoma management and highlights strategies for overcoming these challenges. (C) 2018 American Cancer Society.

引用

页码：2693 / 2703

页数：11

共 82 条

[1] Clinical Outcomes in Metastatic Uveal Melanoma Treated With PD-1 and PD-L1 Antibodies [J].

Algazi, Alain P. ;

Tsai, Katy K. ;

Shoushtari, Alexander N. ;

Munhoz, Rodrigo R. ;

Eroglu, Zeynep ;

Piulats, Josep M. ;

Ott, Patrick A. ;

Johnson, Douglas B. ;

Hwang, Jimmy ;

Daud, Adil I. ;

Sosman, Jeffrey A. ;

Carvajal, Richard D. ;

Chmielowski, Bartosz ;

Postow, Michael A. ;

Weber, Jeffrey S. ;

Sullivan, Ryan J. .

CANCER, 2016, 122 (21) :3344-3353

[2] Expression of Fas and Fas ligand in uveal melanoma: biological implication and prognostic value [J].

Anastassiou, G ;

Coupland, SE ;

Stang, A ;

Boeloeni, R ;

Schilling, H ;

Bornfeld, N .

JOURNAL OF PATHOLOGY, 2001, 194 (04) :466-472

[3]

Aoyama T, 2000, CANCER, V89, P1561, DOI 10.1002/1097-0142(20001001)89:7<1561::AID-CNCR21>3.0.CO

[4]

2-R

[5] Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial [J].

Ascierto, Paolo A. ;

Del Vecchio, Michele ;

Robert, Caroline ;

Mackiewicz, Andrzej ;

Chiarion-Sileni, Vanna ;

Arance, Ana ;

Lebbe, Celeste ;

Bastholt, Lars ;

Hamid, Omid ;

Rutkowski, Piotr ;

McNeil, Catriona ;

Garbe, Claus ;

Loquai, Carmen ;

Dreno, Brigitte ;

Thomas, Luc ;

Grob, Jean-Jacques ;

Liszkay, Gabriella ;

Nyakas, Marta ;

Gutzmer, Ralf ;

Pikiel, Joanna ;

Grange, Florent ;

Hoeller, Christoph ;

Ferraresi, Virginia ;

Smylie, Michael ;

Schadendorf, Dirk ;

Mortier, Laurent ;

Svane, Inge Marie ;

Hennicken, Delphine ;

Qureshi, Anila ;

Maio, Michele .

LANCET ONCOLOGY, 2017, 18 (05) :611-622

[6] Molecular pathways mediating liver metastasis in patients with uveal melanoma [J].

Bakalian, Silvin ;

Marshall, Jean-Claude ;

Logan, Patrick ;

Faingold, Dana ;

Maloney, Shawn ;

Di Cesare, Sebastian ;

Martins, Claudia ;

Fernandes, Bruno F. ;

Burnier, Miguel N., Jr. .

CLINICAL CANCER RESEARCH, 2008, 14 (04) :951-956

[7] Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative [J].

Bogaerts, Jan ;

Sydes, Matthew R. ;

Keat, Nicola ;

McConnell, Andrea ;

Benson, Al ;

Ho, Alan ;

Rotha, Arnaud ;

Fortpied, Catherine ;

Eng, Cathy ;

Peckitt, Clare ;

Coens, Corneel ;

Pettaway, Curtis ;

Arnold, Dirk ;

Hall, Emma ;

Marshall, Ernie ;

Sclafani, Francesco ;

Hatcher, Helen ;

Earl, Helena ;

Ray-Coquard, Isabelle ;

Paul, James ;

Blay, Jean-Yves ;

Whelan, Jeremy ;

Panageas, Kathy ;

Wheatley, Keith ;

Harrington, Kevin ;

Licitra, Lisa ;

Billingham, Lucinda ;

Hensley, Martee ;

McCabe, Martin ;

Patel, Poulam M. ;

Carvajal, Richard ;

Wilson, Richard ;

Glynne-Jones, Rob ;

McWilliams, Rob ;

Leyvraz, Serge ;

Rao, Sheela ;

Nicholson, Steve ;

Filiaci, Virginia ;

Negrouk, Anastassia ;

Lacombe, Denis ;

Dupont, Elisabeth ;

Pauporte, Iris ;

Welch, John J. ;

Law, Kate ;

Trimble, Ted ;

Seymour, Matthew .

EUROPEAN JOURNAL OF CANCER, 2015, 51 (03) :271-281

[8] Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT) [J].

Carvajal, Richard D. ;

Schwartz, Gary K. ;

Mann, Helen ;

Smith, Ian ;

Nathan, Paul D. .

BMC CANCER, 2015, 15

[9] Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma A Randomized Clinical Trial [J].

Carvajal, Richard D. ;

Sosman, Jeffrey A. ;

Quevedo, Jorge Fernando ;

Milhem, Mohammed M. ;

Joshua, Anthony M. ;

Kudchadkar, Ragini R. ;

Linette, Gerald P. ;

Gajewski, Thomas F. ;

Lutzky, Jose ;

Lawson, David H. ;

Lao, Christopher D. ;

Flynn, Patrick J. ;

Albertini, Mark R. ;

Sato, Takami ;

Lewis, Karl ;

Doyle, Austin ;

Ancell, Kristin ;

Panageas, Katherine S. ;

Bluth, Mark ;

Hedvat, Cyrus ;

Erinjeri, Joseph ;

Ambrosini, Grazia ;

Marr, Brian ;

Abramson, David H. ;

Dickson, Mark Andrew ;

Wolchok, Jedd D. ;

Chapman, Paul B. ;

Schwartz, Gary K. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (23) :2397-2405

[10] Oncology Meets Immunology: The Cancer-Immunity Cycle [J].

Chen, Daniel S. ;

Mellman, Ira .

IMMUNITY, 2013, 39 (01) :1-10

← 1 2 3 4 5 6 7 8 9 →